Review
Update on continuous estrogen-progestin replacement therapy
Affiliations
- PMID: 7976988
Item in Clipboard
Review
Update on continuous estrogen-progestin replacement therapy
Am Fam Physician.
.
Abstract
Estrogen replacement therapy is recommended for the prevention of osteoporosis and the attenuation of symptoms associated with menopause. Compliance may be a problem with sequential regimens of estrogen and progestin. To address this issue, continuous-dosing regimens of estrogen and progestin have been used. These regimens cause significantly less cyclic and intermenstrual bleeding and induce amenorrhea in most women, which should enhance compliance.
Similar articles
-
HRT dosing regimens: continuous versus cyclic-pros and cons.Int J Fertil Womens Med. 2001 Jan-Feb;46(1):7-15. Int J Fertil Womens Med. 2001. PMID: 11294619 Review.
-
Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.CMAJ. 1996 Oct 1;155(7):929-34. CMAJ. 1996. PMID: 8837542 Free PMC article. Review.
-
Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.Am J Med. 2005 Dec 19;118 Suppl 12B:64-73. doi: 10.1016/j.amjmed.2005.09.059. Am J Med. 2005. PMID: 16414329
-
Estrogen plus a progestin for prevention of postmenopausal osteoporosis.Med Lett Drugs Ther. 1985 Oct 25;27(699):91-2. Med Lett Drugs Ther. 1985. PMID: 3903458 Clinical Trial. No abstract available.
-
Comparative cardiovascular effects of different progestins in menopause.Int J Fertil Womens Med. 2001 Sep-Oct;46(5):248-56. Int J Fertil Womens Med. 2001. PMID: 11720197 Review.
Cited by
-
Ipriflavone for the treatment of osteoporosis.Osteoporos Int. 1997;7 Suppl 3:S174-8. doi: 10.1007/BF03194367. Osteoporos Int. 1997. PMID: 9536327 Clinical Trial. No abstract available.